Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09IOI
|
|||
| Former ID |
DAP001149
|
|||
| Drug Name |
Amoxapine
|
|||
| Synonyms |
Amoxan; Amoxapina; Amoxapinum; Amoxepine; Ascendin; Asendin; Asendis; Defanyl; Demolox; Desmethylloxapin; Desmethylloxapine; Moxadil; CL 67772; A-129; Amoxapina [INN-Spanish]; Amoxapinum [INN-Latin]; Asendin (TN); Asendis (TN); CL-67772; Defanyl (TN); Demolox (TN); KS-1197; Moxadil (TN); CL-67,772; Amoxapine (JP15/USP/INN); Amoxapine [USAN:BAN:INN:JAN]; 2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin; 2-Chloro-11-(1-piperazinyl)-dibenz[b,f][1,4]oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine; 2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine; 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Approved | [1], [2], [3] | |
| Therapeutic Class |
Antidepressants
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H16ClN3O
|
|||
| Canonical SMILES |
C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
|
|||
| InChI |
1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2
|
|||
| InChIKey |
QWGDMFLQWFTERH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 14028-44-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
855963, 4621375, 7847295, 7978696, 8150155, 8151476, 10321488, 10507662, 11110675, 11110676, 11335411, 11360650, 11363340, 11365902, 11368464, 11371973, 11374794, 11376626, 11461622, 11466130, 11467250, 11484886, 11485759, 11489061, 11490882, 11493032, 11494260, 12013426, 14950373, 17404679, 24278075, 26613170, 26680165, 26747067, 26751577, 29221349, 46509117, 47291025, 47662153, 47662154, 47662155, 47736356, 48110341, 48110342, 48110343, 48259108, 48334368, 48415558, 49698344, 49846684
|
|||
| ChEBI ID |
CHEBI:2675
|
|||
| ADReCS Drug ID | BADD_D00128 | |||
| SuperDrug ATC ID |
N06AA17
|
|||
| SuperDrug CAS ID |
cas=014028445
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Amoxapine (adjusted p-values: 3.46E-05). | |||
|
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides merdae was decreased by Amoxapine (adjusted p-values: 8.49E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Norepinephrine transporter (NET) | Target Info | Inhibitor | [5] |
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | Monoamine Transport | |||
| NRF2 pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 201). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 072688. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.